Spots Global Cancer Trial Database for abemaciclib
Every month we try and update this database with for abemaciclib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | NCT03939897 | Anatomic Stage ... Metastatic Brea... Metastatic HER2... Metastatic Horm... Recurrent Breas... | Abemaciclib Biopsy Biospecimen Col... Copanlisib Hydr... Diagnostic Imag... Echocardiograph... Fulvestrant Multigated Acqu... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | NCT04220892 | High Grade Glio... | Pembrolizumab Pemetrexed Abemaciclib | 18 Years - | Saint John's Cancer Institute | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | NCT03280563 | Breast Neoplasm... | Atezolizumab (M... Bevacizumab Entinostat Exemestane Fulvestrant Ipatasertib Tamoxifen Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | NCT05095207 | Breast Cancer Metastasis | Abemaciclib Bicalutamide | 18 Years - 90 Years | Icahn School of Medicine at Mount Sinai | |
| A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | NCT04514159 | Breast Cancer | ZN-c5 Abemaciclib | 18 Years - | Zeno Alpha Inc. | |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | NCT05999994 | Neoplasms Child Adolescent | Ramucirumab Cyclophosphamid... Vinorelbine Gemcitabine Docetaxel Abemaciclib Irinotecan Temozolomide | 1 Year - 39 Years | Eli Lilly and Company | |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | NCT06188520 | ER+ HER2- Advan... High-grade Sero... | AZD8421 Camizestrant Ribociclib Palbociclib Abemaciclib | 18 Years - | AstraZeneca | |
| Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC | NCT04565054 | Breast Cancer F... | Abemaciclib 50 ... | 18 Years - | West German Study Group | |
| A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) | NCT02411591 | Carcinoma, Non-... Neoplasm Metast... | Necitumumab Abemaciclib | 18 Years - | Eli Lilly and Company | |
| A Study of LY2835219 in Participants With Cancer | NCT02117648 | Neoplasm Neoplasm Metast... | Abemaciclib Clarithromycin | 18 Years - | Eli Lilly and Company | |
| Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) | NCT04227327 | Advanced Breast... | Abemaciclib Aromatase Inhib... | 18 Years - | University of Milano Bicocca | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | NCT04961996 | Early Breast Ca... | Giredestrant Endocrine Thera... LHRH Agonist Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | NCT03781960 | Hepatocellular ... | Abemaciclib Nivolumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | NCT03220646 | Brain Tumor | abemaciclib abemaciclib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy | NCT03356587 | HNSCC Head and Neck N... | Abemaciclib | 20 Years - | Seoul National University Hospital | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | NCT03763604 | Metastatic Brea... | Abemaciclib | 18 Years - | Eli Lilly and Company | |
| Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer | NCT05169567 | Breast Neoplasm Neoplasm Metast... | Abemaciclib Fulvestrant Placebo | 18 Years - | Eli Lilly and Company | |
| Abemaciclib in Newly Diagnosed Meningioma Patients | NCT05940493 | Meningioma | Abemaciclib Placebo | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer | NCT02450539 | Non-Small Cell ... | Abemaciclib Docetaxel | 18 Years - | Eli Lilly and Company | |
| A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy | NCT03356587 | HNSCC Head and Neck N... | Abemaciclib | 20 Years - | Seoul National University Hospital | |
| Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | NCT04040205 | Chondrosarcoma Osteosarcoma Soft Tissue Sar... | Abemaciclib | 18 Years - | Medical College of Wisconsin | |
| Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | NCT04305834 | Anatomic Stage ... Hormone Recepto... Metastatic Brea... Prognostic Stag... | Abemaciclib Questionnaire A... | 70 Years - | City of Hope Medical Center | |
| Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients | NCT02831530 | Breast Cancer | Abemaciclib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | NCT03763604 | Metastatic Brea... | Abemaciclib | 18 Years - | Eli Lilly and Company | |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | NCT05307705 | Breast Cancer | LOXO-783 Fulvestrant Imlunestrant Abemaciclib Anastrozole, Ex... Paclitaxel | 18 Years - | Eli Lilly and Company | |
| A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | NCT03706365 | Prostate Cancer | Abemaciclib Abiraterone Ace... Prednisone Placebo | 18 Years - | Eli Lilly and Company | |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | NCT04750928 | Neurofibromatos... | Abemaciclib | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | NCT03310879 | Cancer | Abemaciclib | 18 Years - | Dana-Farber Cancer Institute | |
| Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | NCT03763604 | Metastatic Brea... | Abemaciclib | 18 Years - | Eli Lilly and Company | |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | NCT05372640 | Breast Carcinom... Malignant Solid... NUT Carcinoma | Abemaciclib BET Bromodomain... Biopsy Biospecimen Col... Diagnostic Imag... | 12 Years - | National Cancer Institute (NCI) | |
| Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | NCT03284957 | Breast Cancer | Amcenestrant Palbociclib Alpelisib Everolimus Abemaciclib | 18 Years - | Sanofi | |
| ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | NCT04603183 | Breast Cancer M... | Abemaciclib Paclitaxel Letrozole Fulvestrant | 18 Years - | MedSIR | |
| Abemaciclib + Pembrolizumab In Glioblastoma | NCT04118036 | Glioblastoma | Pembrolizumab Abemaciclib | 18 Months - | Dana-Farber Cancer Institute | |
| Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer | NCT05872204 | Low Grade Serou... Adult Type Gran... | Abemaciclib Letrozole | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | NCT04165031 | Advanced Solid ... Non-Small Cell ... Colorectal Canc... | LY3499446 Abemaciclib Cetuximab Erlotinib Docetaxel | 18 Years - | Eli Lilly and Company | |
| Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib | NCT05464173 | Breast Cancer | Chidamide Abemaciclib endocrinotherap... | 18 Years - | Fudan University | |
| Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | NCT02792725 | Metastatic Brea... | Abemaciclib | 18 Years - | Eli Lilly and Company | |
| ETHAN - ET for Male BC | NCT05501704 | Male Breast Can... Hormone Recepto... Hormone Recepto... | Tamoxifen Anastrozole Degarelix Abemaciclib | 18 Years - | Dana-Farber Cancer Institute | |
| Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer | NCT05872204 | Low Grade Serou... Adult Type Gran... | Abemaciclib Letrozole | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | NCT06179303 | Anatomic Stage ... Anatomic Stage ... Locally Advance... Locally Advance... Metastatic HER2... Metastatic Horm... | Abemaciclib Anastrozole Biospecimen Col... Computed Tomogr... Diagnostic Imag... Exemestane Fludeoxyglucose... Fluorine F 18 F... Fulvestrant Gonadotropin-re... Letrozole Positron Emissi... Tamoxifen Therapeutic Est... | 18 Years - | University of Washington | |
| Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | NCT03655444 | Head and Neck S... | Abemaciclib Nivolumab Tumor biopsy Peripheral bloo... EORTC QLQ-30 | 18 Years - | Washington University School of Medicine | |
| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | NCT04633239 | Recurrent Ovari... Recurrent Plati... | Abemaciclib Biopsy Biospecimen Col... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | NCT04603183 | Breast Cancer M... | Abemaciclib Paclitaxel Letrozole Fulvestrant | 18 Years - | MedSIR | |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | NCT04486352 | Endometrial Can... | Atezolizumab - ... Bevacizumab Ipatasertib Talazoparib Trastuzumab emt... Tiragolumab Atezolizumab - ... Inavolisib Letrozole Giredestrant Abemaciclib | 18 Years - | Alliance Foundation Trials, LLC. | |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | NCT03310879 | Cancer | Abemaciclib | 18 Years - | Dana-Farber Cancer Institute | |
| Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | NCT04921904 | Metastatic Esop... Metastatic Gast... | Abemaciclib Ramucirumab | 18 Years - | Baylor Research Institute | |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | NCT05617885 | Metastatic Pros... Non-metastatic ... Prostate Cancer | Darolutamide Abemaciclib GNRH-A Leuproli... GNRH-A Gosereli... Degarelix | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | NCT03905889 | Renal Cell Carc... | Abemaciclib Sunitinib | 18 Years - | Brown University | |
| VS-6766+Abema+Fulv in Met HR+/HER- BC | NCT05608252 | Breast Cancer Hormone Recepto... Hormone Recepto... | VS-6766 Abemaciclib Fulvestrant | 18 Years - | Dana-Farber Cancer Institute | |
| Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer | NCT03938337 | Head and Neck C... | Cohort 1 Not Pr... Cohort 2 Treate... | 18 Years - | University of Alabama at Birmingham | |
| Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer | NCT05169567 | Breast Neoplasm Neoplasm Metast... | Abemaciclib Fulvestrant Placebo | 18 Years - | Eli Lilly and Company | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer | NCT04071262 | Advanced Cancer | Abemaciclib Abiraterone Ace... Prednisolone | 20 Years - | Eli Lilly and Company | |
| Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | NCT03284957 | Breast Cancer | Amcenestrant Palbociclib Alpelisib Everolimus Abemaciclib | 18 Years - | Sanofi | |
| A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | NCT02981342 | Pancreatic Duct... | Abemaciclib LY3023414 Gemcitabine Capecitabine | 18 Years - | Eli Lilly and Company | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer | NCT04071262 | Advanced Cancer | Abemaciclib Abiraterone Ace... Prednisolone | 20 Years - | Eli Lilly and Company | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | NCT04351230 | Anatomic Stage ... HER2 Positive B... Metastatic Brea... Prognostic Stag... | Abemaciclib Trastuzumab Emt... | 18 Years - | Academic and Community Cancer Research United | |
| LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | NCT04391595 | Glioblastoma GBM Glioma | Abemaciclib LY3214996 | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | NCT03846583 | Breast Cancer | Tucatinib Abemaciclib Trastuzumab Aromatase Inhib... | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer | NCT03703466 | Metastatic Brea... | Abemaciclib | 18 Years - | Eli Lilly and Company | |
| TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | NCT06001762 | Breast Cancer Early-stage Bre... High Risk Breas... | Abemaciclib Tamoxifen Anastrozole Letrozole Exemestane LHRH Agonist | 18 Years - | Dana-Farber Cancer Institute | |
| A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | NCT04534283 | Cancer Cancer Metastat... BRAF V600E MEK1 Gene Mutat... MEK2 Gene Mutat... ERK Mutation RAF1 Gene Mutat... | Abemaciclib LY3214996 | 18 Years - | Indiana University | |
| Study of Abemaciclib in Dedifferentiated Liposarcoma | NCT02846987 | Sarcoma Dedifferentiate... | Abemaciclib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | NCT05952557 | Breast Cancer, ... | Camizestrant Tamoxifen Anastrozole Letrozole Exemestane Abemaciclib | 18 Years - 130 Years | AstraZeneca | |
| Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | NCT04552769 | Thyroid Cancer Anaplastic Thyr... Undifferentiate... | Abemaciclib | 18 Years - | Stanford University | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | NCT04092673 | Solid Tumor, Ad... | eFT226 Sotorasib Fulvestrant Abemaciclib Trastuzumab | 18 Years - | Effector Therapeutics | |
| A Study of Abemaciclib in Recurrent Glioblastoma | NCT02981940 | Glioblastoma | Abemaciclib Surgery | 18 Years - | Dana-Farber Cancer Institute | |
| Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer | NCT04298983 | Prostate Cancer | Abemaciclib 150... Androgen depriv... Radiation Thera... | 18 Years - | University of Alabama at Birmingham | |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | NCT04941274 | Kaposi Sarcoma | Abemaciclib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) | NCT06169371 | Breast Cancer | Abemaciclib Abemaciclib Abemaciclib Abemaciclib | 18 Years - | University of Illinois at Chicago | |
| A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | NCT03905889 | Renal Cell Carc... | Abemaciclib Sunitinib | 18 Years - | Brown University | |
| Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer | NCT04305236 | Breast Neoplasm Hormone Recepto... | Abemaciclib Fulvestrant | 18 Years - | University of California, Irvine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
